John D. England
LSU Health Sciences Center New Orleans
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by John D. England.
Diabetes Care | 2010
Solomon Tesfaye; Andrew J.M. Boulton; Peter James Dyck; Roy Freeman; Michael Horowitz; P. Kempler; Giuseppe Lauria; Rayaz Malik; Vincenza Spallone; Aaron I. Vinik; Luciano Bernardi; Paul Valensi; James W. Albers; Gérard Amarenco; Henning Anderson; Joe Arezzo; M. Backonja; Geert Jan Biessels; Vera Bril; Norman E. Cameron; Mary A. Cotter; John D. England; Eva L. Feldman; Simona Frontoni; Jannik Hilsted; Philip Low; Rayaz A. Malik; Peter C. O'Brien; Rodica Pop-Busui; Bruce A. Perkins
Preceding the joint meeting of the 19th annual Diabetic Neuropathy Study Group of the European Association for the Study of Diabetes (NEURODIAB) and the 8th International Symposium on Diabetic Neuropathy in Toronto, Canada, 13–18 October 2009, expert panels were convened to provide updates on classification, definitions, diagnostic criteria, and treatments of diabetic peripheral neuropathies (DPNs), autonomic neuropathy, painful DPNs, and structural alterations in DPNs.
Neurology | 2005
John D. England; Gary S. Gronseth; Gary M. Franklin; Robert G. Miller; Arthur K. Asbury; Gregory T. Carter; Jeffrey A. Cohen; Morris A. Fisher; James F. Howard; Laurence J. Kinsella; Norman Latov; Richard A. Lewis; Phillip A. Low; Austin J. Sumner
The objective of this report was to develop a case definition of distal symmetric polyneuropathy to standardize and facilitate clinical research and epidemiologic studies. A formalized consensus process was employed to reach agreement after a systematic review and classification of evidence from the literature. The literature indicates that symptoms alone have relatively poor diagnostic accuracy in predicting the presence of polyneuropathy; signs are better predictors of polyneuropathy than symptoms; and single abnormalities on examination are less sensitive than multiple abnormalities in predicting the presence of polyneuropathy. The combination of neuropathic symptoms, signs, and electrodiagnostic findings provides the most accurate diagnosis of distal symmetric polyneuropathy. A set of case definitions was rank ordered by likelihood of disease. The highest likelihood of polyneuropathy (useful for clinical trials) occurs with a combination of multiple symptoms, multiple signs, and abnormal electrodiagnostic studies. A modest likelihood of polyneuropathy (useful for field or epidemiologic studies) occurs with a combination of multiple symptoms and multiple signs when the results of electrodiagnostic studies are not available. A lower likelihood of polyneuropathy occurs when electrodiagnostic studies and signs are discordant. For research purposes, the best approach to defining distal symmetric polyneuropathy is a set of case definitions rank ordered by estimated likelihood of disease. The inclusion of this formalized case definition in clinical and epidemiologic research studies will ensure greater consistency of case selection.
Neurology | 2009
Robert G. Miller; Carlayne E. Jackson; Edward J. Kasarskis; John D. England; Dallas Forshew; Wendy Johnston; Sanjay Kalra; Jonathan S. Katz; Hiroshi Mitsumoto; Jeffrey Rosenfeld; Christen Shoesmith; Michael J. Strong; Susan C. Woolley
Objective: To systematically review evidence bearing on the management of patients with amyotrophic lateral sclerosis (ALS). Methods: The authors analyzed studies from 1998 to 2007 to update the 1999 practice parameter. Topics covered in this section include slowing disease progression, nutrition, and respiratory management for patients with ALS. Results: The authors identified 8 Class I studies, 5 Class II studies, and 43 Class III studies in ALS. Important treatments are available for patients with ALS that are underutilized. Noninvasive ventilation (NIV), percutaneous endoscopic gastrostomy (PEG), and riluzole are particularly important and have the best evidence. More studies are needed to examine the best tests of respiratory function in ALS, as well as the optimal time for starting PEG, the impact of PEG on quality of life and survival, and the effect of vitamins and supplements on ALS. Recommendations: Riluzole should be offered to slow disease progression (Level A). PEG should be considered to stabilize weight and to prolong survival in patients with ALS (Level B). NIV should be considered to treat respiratory insufficiency in order to lengthen survival (Level B), and may be considered to slow the decline of forced vital capacity (Level C) and improve quality of life (Level C). Early initiation of NIV may increase compliance (Level C), and insufflation/exsufflation may be considered to help clear secretions (Level C).
Neurology | 2011
Vera Bril; John D. England; Gary M. Franklin; Misha-Miroslav Backonja; Jeffrey A. Cohen; David R. Del Toro; Eva L. Feldman; Donald J. Iverson; Bruce A. Perkins; James W. Russell; Douglas W. Zochodne
Objective: To develop a scientifically sound and clinically relevant evidence-based guideline for the treatment of painful diabetic neuropathy (PDN). Methods: We performed a systematic review of the literature from 1960 to August 2008 and classified the studies according to the American Academy of Neurology classification of evidence scheme for a therapeutic article, and recommendations were linked to the strength of the evidence. The basic question asked was: “What is the efficacy of a given treatment (pharmacologic: anticonvulsants, antidepressants, opioids, others; and nonpharmacologic: electrical stimulation, magnetic field treatment, low-intensity laser treatment, Reiki massage, others) to reduce pain and improve physical function and quality of life (QOL) in patients with PDN?” Results and Recommendations: Pregabalin is established as effective and should be offered for relief of PDN (Level A). Venlafaxine, duloxetine, amitriptyline, gabapentin, valproate, opioids (morphine sulfate, tramadol, and oxycodone controlled-release), and capsaicin are probably effective and should be considered for treatment of PDN (Level B). Other treatments have less robust evidence or the evidence is negative. Effective treatments for PDN are available, but many have side effects that limit their usefulness, and few studies have sufficient information on treatment effects on function and QOL.
Pm&r | 2009
John D. England; Gary S. Gronseth; Gary M. Franklin; Gregory T. Carter; Laurence J. Kinsella; Jeffrey A. Cohen; Arthur K. Asbury; Kinga Szigeti; James R. Lupski; Norman Latov; Richard A. Lewis; Phillip A. Low; Morris A. Fisher; David N. Herrmann; James F. Howard; G. Lauria; Robert G. Miller; Michael Polydefkis; Austin J. Sumner
Distal symmetric polyneuropathy (DSP) is the most common variety of neuropathy. Since the evaluation of this disorder is not standardized, the available literature was reviewed to provide evidence‐based guidelines regarding the role of autonomic testing, nerve biopsy and skin biopsy for the assessment of polyneuropathy.
Pm&r | 2009
John D. England; Gary S. Gronseth; Gary M. Franklin; Gregory T. Carter; Laurence J. Kinsella; Jeffrey A. Cohen; Arthur K. Asbury; Kinga Szigeti; James R. Lupski; Norman Latov; Richard A. Lewis; Phillip A. Low; Morris A. Fisher; David N. Herrmann; James F. Howard; G. Lauria; Robert G. Miller; Michael Polydefkis; Austin J. Sumner
Distal symmetric polyneuropathy (DSP) is the most common variety of neuropathy. Since the evaluation of this disorder is not standardized, the available literature was reviewed to provide evidence‐based guidelines regarding the role of laboratory and genetic tests for the assessment of DSP.
Pm&r | 2011
Vera Bril; John D. England; Gary M. Franklin; Miroslav Backonja; Jeffrey A. Cohen; David R. Del Toro; Eva L. Feldman; Donald J. Iverson; Bruce A. Perkins; James W. Russell; Douglas W. Zochodne
To develop a scientifically sound and clinically relevant evidence‐based guideline for the treatment of painful diabetic neuropathy (PDN).
Muscle & Nerve | 2009
John D. England; Gary S. Gronseth; Gary M. Franklin; Gregory T. Carter; Laurence J. Kinsella; Jeffrey A. Cohen; Arthur K. Asbury; Kinga Szigeti; James R. Lupski; Norman Latov; Richard A. Lewis; Phillip A. Low; Morris A. Fisher; David N. Herrmann; James F. Howard; Giuseppe Lauria; Robert G. Miller; Michael Polydefkis; Austin J. Sumner
Distal symmetric polyneuropathy (DSP) is the most common variety of neuropathy. Since the evaluation of this disorder is not standardized, the available literature was reviewed to provide evidence‐based guidelines regarding the role of autonomic testing, nerve biopsy, and skin biopsy for the assessment of polyneuropathy. A literature review using MEDLINE, EMBASE, Science Citation Index, and Current Contents was performed to identify the best evidence regarding the evaluation of polyneuropathy published between 1980 and March 2007. Articles were classified according to a four‐tiered level of evidence scheme and recommendations were based on the level of evidence. (1) Autonomic testing may be considered in the evaluation of patients with polyneuropathy to document autonomic nervous system dysfunction (Level B). Such testing should be considered especially for the evaluation of suspected autonomic neuropathy (Level B) and distal small fiber sensory polyneuropathy (SFSN) (Level C). A battery of validated tests is recommended to achieve the highest diagnostic accuracy (Level B). (2) Nerve biopsy is generally accepted as useful in the evaluation of certain neuropathies as in patients with suspected amyloid neuropathy, mononeuropathy multiplex due to vasculitis, or with atypical forms of chronic inflammatory demyelinating polyneuropathy (CIDP). However, the literature is insufficient to provide a recommendation regarding when a nerve biopsy may be useful in the evaluation of DSP (Level U). (3) Skin biopsy is a validated technique for determining intraepidermal nerve fiber (IENF) density and may be considered for the diagnosis of DSP, particularly SFSN (Level C). There is a need for additional prospective studies to define more exact guidelines for the evaluation of polyneuropathy. Muscle Nerve 39: 106–115, 2009
Muscle & Nerve | 2011
Vera Bril; John D. England; Gary M. Franklin; Miroslav Backonja; Jeffrey A. Cohen; David R. Del Toro; Eva L. Feldman; Donald J. Iverson; Bruce A. Perkins; James W. Russell; Douglas W. Zochodne
The objective of this report was to develop a scientifically sound and clinically relevant evidence‐based guideline for the treatment of painful diabetic neuropathy (PDN). The basic question that was asked was: “What is the efficacy of a given treatment (pharmacological: anticonvulsants, antidepressants, opioids, others; non‐pharmacological: electrical stimulation, magnetic field treatment, low‐intensity laser treatment, Reiki massage, others) to reduce pain and improve physical function and quality of life (QOL) in patients with PDN?” A systematic review of literature from 1960 to August 2008 was performed, and studies were classified according to the American Academy of Neurology classification of evidence scheme for a therapeutic article. Recommendations were linked to the strength of the evidence. The results indicate that pregabalin is established as effective and should be offered for relief of PDN (Level A). Venlafaxine, duloxetine, amitriptyline, gabapentin, valproate, opioids (morphine sulfate, tramadol, and oxycodone controlled‐release), and capsaicin are probably effective and should be considered for treatment of PDN (Level B). Other treatments have less robust evidence, or the evidence is negative. Effective treatments for PDN are available, but many have side effects that limit their usefulness. Few studies have sufficient information on their effects on function and QOL. Muscle Nerve, 2011.
Pm&r | 2011
Vera Bril; John D. England; Gary M. Franklin; Miroslav Backonja; Jeffrey M. Cohen; David R. Del Toro; Eva L. Feldman; Donald J. Iverson; Bruce A. Perkins; James W. Russell; Douglas W. Zochodne
To develop a scientifically sound and clinically relevant evidence‐based guideline for the treatment of painful diabetic neuropathy (PDN).